Pancreatic cancer
Conditions
Interventions
investigational material(s)
Generic name etc : erlotinibhydrochloride
INN of investigational material :
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigat
Sponsors
Chugai Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria - Histologically or cytologically confirmed diagnosis of adenocarcinoma or adenosquamous of the pancreas cancer which is unresectable (locally advanced or metastatic). - ECOG performance status (PS) of 0, 1 or 2. - Adequate organ functions Exclusion criteria - The patient is currently suffering from such pulmonary disorders as sudden pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, active radioactive pneumonia, or drug-related pneumonia, or he/she has a history of such disease. - Patients have thoracic radiotherapy. - Prior treatment with Gemcitabine - Patients who have had treatment with any investigational drug within 4 weeks prior to entry. - Patients who have history of serious hypersensitivity reactions with any medicine.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety (feasibility), efficacy | — |
Outcome results
None listed